Gregory Norden - 08 Aug 2025 Form 4 Insider Report for Royalty Pharma plc (RPRX)

Reporting relationship: Director
Issuer ticker: RPRX
Reported as of: 08 Aug 2025
Net transaction value: -$1,213,749
SEC form: 4
Accepted by SEC: 11 Aug 2025, 16:35:58 UTC
Prior SEC filing: 27 Jun 2025
Next SEC filing: 19 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Sean Weisberg, as Attorney-in-Fact for Gregory Norden

Key filing fact

Gregory Norden filed Form 4 for Royalty Pharma plc (RPRX) on 11 Aug 2025.

Key facts

This page summarizes Gregory Norden's Form 4 filing for Royalty Pharma plc (RPRX).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 11 Aug 2025, 16:35.

Change

Previous filing in this sequence was filed on 27 Jun 2025.
Current net transaction value: -$1,213,749.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001405104 Primary reporting owner

Norden Gregory

Relationship: Director
Address: C/O ROYALTY PHARMA PLC, 110 E. 59TH STREET, NEW YORK
Signature: /s/ Sean Weisberg, as Attorney-in-Fact for Gregory Norden
Signature date: 11 Aug 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RPRX transaction

Class A Ordinary Shares

Conversion of derivative security

Transaction value: $0
Shares: +144,660
Change %: +173%
Price: $0.000000
Shares after: 228,348
Date: 08 Aug 2025
Ownership: Direct
Footnotes: F1

RPRX transaction

Class A Ordinary Shares

Sale

Transaction value: $1,213,749
Shares: -33,500
Change %: -15%
Price: $36.23
Shares after: 194,848
Date: 11 Aug 2025
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RPRX transaction Derivative

LP interests in RPI US Partners 2019, LP

Conversion of derivative security

Transaction value: $0
Shares: -14,466
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 08 Aug 2025
Ownership: Direct
Underlying class: Class A Ordinary Shares
Underlying amount: 144,660
Exercise price: $0.000000
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Amended and Restated Exchange Agreement. No additional value will be paid by the Reporting Person in connection with the exchange.

Footnote F2

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.10 to $36.40 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F3

Represents limited partnership interests in RPI US Partners 2019, LP ("RPI US LP Interests"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value.